Nicholas A. Meanwell received his B.Sc. (1976) and Ph.D. (1979) degrees from the University of Sheffield, England and conducted post-doctoral studies at Wayne State University, Detroit, Michigan. In 1982, he joined Bristol-Myers Squibb Research and Development where he is currently an Executive Director in the Department of Discovery Chemistry and Molecular Technologies. He has led drug discovery programs in the cardiovascular, neurosciences and virology therapeutic areas, work that has resulted in the advancement of 30 clinical candidates that includes temsavir/fostemsavir for the treatment of HIV-1 infection, the HCV NS5A inhibitor daclatasvir, marketed as DaklinzaTM, and the HCV NS3 protease inhibitor asunaprevir, marketed as SunvepraTM. He is the author/co-author of 210 publications, review articles and book chapters and more than 180 meeting abstracts and is named as an inventor/co-inventor of 118 issued U.S. Patents. He has presented over 100 invited lectures at National and International meetings, Universities and Schools on Medicinal Chemistry and has organized/co-organized/presided of over 30 sessions at National and International Meetings, ACS Webinars in Drug Discovery, ACS Prospectives Meetings and Short Courses.
He was admitted as a member of the Connecticut Academy of Science and Engineering in February, 2014, was the co-recipient of a PhRMA Research and Hope Award for Biopharmaceutical Industry Research, 2014 for outstanding research in the area of HIV/AIDS, the recipient of the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award administered jointly by the ACS Division of Medicinal Chemistry and the Journal of Medicinal Chemistry and he was inducted into the ACS Division of Medicinal Chemistry Hall of Fame on August 18th, 2015.